Click on headlines below to download research

Positive clinical step forward in SDC-1801
Sareum Holdings | 19/02/2024

Sareum Holdings has announced positive clinical progression for SDC-1801, its lead asset and novel TYK2/JAK1 inhibitor targeting the autoimmune space (with…

SRA737 – new partnership to kick off the year
Sareum Holdings | 03/01/2024

Sareum Holdings’ co-development partner CRT Pioneer Fund (CPF) has signed a new licensing agreement with an unnamed US-based private biopharma company…

SDC-1801 embarks on clinical journey in FY23
Sareum Holdings | 12/10/2023

Sareum Holdings recently announced its FY23 results and the key highlight, which was initiation of the clinical development of SDC-1801, its lead asset,…